Status:
COMPLETED
Sequences of Aerobic and Resistance Exercise and Cardio-metabolic Functions in T2D
Lead Sponsor:
Zhejiang University
Collaborating Sponsors:
Nanjing Sport Institute
Karolinska Institutet
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
50-70 years
Phase:
NA
Brief Summary
Aerobic exercise and resistance exercise are two types of exercise commonly used in physical conditioning. Compared to aerobic exercise, a combination of aerobic and resistance exercise has been linke...
Detailed Description
Objectives: This randomized study aims to explore the effects of aerobic and resistance training sequences on glycemic control among type 2 diabetes (T2D) patients through an 8-wk combined aerobic an...
Eligibility Criteria
Inclusion
- Age 50-70 years;
- Type 2 diabetes diagnosed as: random blood glucose ≥11.1mmol/L (200mg/dL) or fasting blood glucose ≥7.0mmol/L (126mg/L) or oral glucose tolerance test (2h) ≥11.1mmol/L (200mg/dL) or glycated hemoglobin (HbA1c) ≥ 6.5%;
- The course of type 2 diabetes lasted for one year or longer;
- Willing to participate and sign the informed consent form voluntarily
Exclusion
- Type 1 diabetes;
- Fasting blood glucose (FBG)\>16.7mmol/L;
- Severe complications of diabetes such as acute infection, diabetic ketoacidosis, and plantar lesions;
- Severe kidney disease, cardiovascular and cerebrovascular diseases as identified by a specialist;
- Musculoskeletal, neurological, psychiatric or other disorders which limit the ability to exercise as identified by a specialist;
- Doing physical exercise regularly (≥ 3 times per week, at least 1 hour per session of moderate to vigorous activities);
- Currently under dietary program for weight loss;
- Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at rest;
- Abnormal electrocardiogram (rest and exercise);
- Other comorbidities or medications irrelevant to diabetes treatment that may influence glycemia during the past 6 months
Key Trial Info
Start Date :
September 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 2 2024
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT06145542
Start Date
September 25 2023
End Date
July 2 2024
Last Update
April 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maigaoqiao Community Health Service Center
Nanjing, Jiangsu, China, 210000